Celebrating ICER’s Impact Over the Last 20+ Years
This year, ICER is celebrating our 20th anniversary. This mileston has given us an opportunity to reflect on the impact of our organization, especially in shaping how evidence and value inform drug pricing and other health care interventions in the U.S. health care system.
For 20 years, we have been at the forefront of bringing both rigorous evidence and an open dialogue into decisions about health care interventions, from prescription drugs to diagnostics, cell and gene therapies, and other treatments. Throughout that time, we have maintained our independence as a non-profit research organization.
Today, ICER’s work has informed policy debates, payer decisions, and negotiations across the country. In fact, most public and private payers have relied on ICER’s assessments to help guide coverage and pricing decisions in one way or another. But more than any single evaluation or review, we are most proud of the advancements ICER has helped lead around fair pricing, fair access, and future innovation. It has been a conversation grounded in evidence and shaped by patient experiences.
And while ICER has influenced conversations on drug pricing significantly in the last 20 years, there is more work to be done. As we look toward the future, our commitment remains as true as it was when we were starting as a small research program at Harvard Medical School within Mass General Hospital; to use evidence and engagement to ensure fair pricing. In this rapidly evolving health care landscape, ICER’s mission is more vital than ever, and we are energized by the opportunity to help shape the health system for the next 20 years and beyond.